THE "NEW" PROSTATE CANCER INFOLINK

Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year.

What we can now confirm for you is what we expected, that the data from both of these trials were submitted as late-breaking abstracts (LBAs) for presentation at the ASCO meeting, and so even the abstracts will not be available until the day of their presentation (on the afternoon of Sunday, June 4) in Chicago.

As mentioned previously,

• The results of the LATITUDE trial will provide us with data on the effectiveness and safety of abiraterone acetate (Zytiga) + prednisone in men newly diagnosed, high-risk, metastatic, hormone-naive prostate cancer.
• The results of Arm G of the STAMPEDE trial will tell us about the effectiveness and safety of adding abiraterone acetate + prednisone to standard, long-term androgen deprivation therapy (ADT) in men with high-risk prostate cancer  starting long-term ADT with an LHRH agonist.

We’re just going to need to be patient for another couple of weeks to hear the results of these two studies.

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, outcome, trial, Zytiga |